IPO
IPO Latest Updates DailyLive GMP & Prospectus Intelligence
IPO Review· 8 min read

Symbiotec Pharmalab IPO: Price Band, Steroid API Moat & GMP Review

A ₹1,450 Cr mainboard pharma issue specializing in high-margin steroid and hormone APIs. Full audit of global export market, financials and listing expectations.

ED
IPOSathi DeskPrimary Market Desk

Published on · Verified Analysis

SEBI Regulatory & RED Audited
S
Latest Updates Daily

Editorial Key Takeaways

This analysis is based on official Draft Red Herring Prospectus (DRED) filings, historical peer valuation multiples, and exchange data. Figures are audited for institutional accuracy.

In This Article

  1. 1.1. Issue Overview
  2. 2.2. Business Moat: High-Barrier Steroid & Hormone APIs
  3. 3.3. Financial Metrics & Valuation
  4. 4.Verdict

Specialty active pharmaceutical ingredient (API) manufacturer Symbiotec Pharmalab Limited is closing its ₹1,450 Crore Mainboard IPO on 27 August 2026 with a price band of ₹938 to ₹988 per share.

Symbiotec is one of the few global manufacturers focused exclusively on complex steroid and hormone APIs, supplying top multinational pharmaceutical companies in over 40 countries.

1. Issue Overview

ParameterDetails
**Price Band**₹938 to ₹988 per share
**Lot Size**15 Equity Shares
**Minimum Retail Bid**₹14,820 (1 Lot at cut-off)
**Issue Size**₹1,450 Crore
**Closes On**27 August 2026
**Allotment Date**28 August 2026
**Listing Date**1 September 2026 (NSE & BSE Mainboard)

2. Business Moat: High-Barrier Steroid & Hormone APIs

Steroid and hormone API manufacturing requires USFDA and EU-GMP compliant dedicated facilities with stringent containment capabilities.

  • USFDA Approved Plants: Operates advanced USFDA-inspected manufacturing units in Indore, Madhya Pradesh.
  • Export Dominance: Over 70% of revenues are generated from regulated export markets including the US, Europe, and Japan.
  • High Entry Barriers: Complex chemical synthesis processes make customer switching costs extremely high.

    • 3. Financial Metrics & Valuation

    Financial MetricFY24FY25FY26 (P)
    **Revenue from Operations**₹620 Crore₹780 Crore₹960 Crore
    **EBITDA Margin**24.5%26.8%28.2%
    **Net Profit (PAT)**₹95 Crore₹135 Crore₹180 Crore

    At ₹988 upper band, the stock trades at ~24.5x FY26 P/E, presenting an attractive valuation compared to listed API peers like Divi's Laboratories (~60x P/E) and Solara Active Pharma.

    Verdict

    With strong USFDA compliance, high 28% EBITDA margins, and competitive pricing, Symbiotec Pharmalab IPO represents a solid fundamental pick for healthcare and pharma investors.

    *Disclaimer: Educational breakdown only. Please consult a SEBI-registered advisor.*

    ED

    About IPOSathi Desk

    Primary Market Analyst & Senior Financial Journalist · IPO Latest Updates Daily

    Our research desk specializes in reading SEBI Red Herring Prospectuses, institutional anchor allocations, and forensic balance sheet audits. Every report follows rigorous E-E-A-T research standards without promoter sponsorship.